Reversal of Multidrug Resistance by New Dihydropyridines with Low Calcium Antagonist Activity

Capolongo, Laura; Amboldi, Nadia; Ballinari, Dario; Cozzi, Paolo; Melegaro, Giulia; Ripamonti, Marina; Vaghi, Fabrizio; Grandi, Maria

doi:10.3109/02841869409083949

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(3)) [13,14]. These findings were in agreement with the previous work of Capolongo et al [15] and were confirmed by other investigators (Fig. (3)) [16].…”

Section: 4-dhps As Multi Drug Resistance Reverterssupporting

confidence: 93%

1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story So Far And Perspectives (Part 2): Action in Other Targets and Antitargets

Carosati¹,

Ioan²,

Micucci³

et al. 2012

CMC

129

View full text Add to dashboard Cite

1,4-Dihydropyridines were introduced in the last century for the treatment of coronary diseases. Then medicinal chemists decorated the 1,4-DHP nucleus, the most studied scaffold among L-type calcium channel blockers, achieving diverse activities at several receptors, channels and enzymes. We already described (Ioan et al. Curr. Med. Chem. 2011, 18, 4901-4922) the effects of 1,4-DHPs at ion channels and G-protein coupled receptors. In this paper we continue the analysis of the wide range of biological effects exerted by compounds belonging to this chemical class. In particular, focus is given to the ability of 1,4-DHPs to revert multi drug resistance that, after over 20 years of research, continues to be of great interest. We also describe activities on other targets and the action of 1,4-DHPs against several diseases. Finally, we report and review the interaction of 1,4-DHPs with the hERG channel, transporters and phase I metabolizing enzymes. This work is a starting point for further exploration of the 1,4-DHP core activities on targets, off-targets and antitargets.

show abstract

“…(3)) [13,14]. These findings were in agreement with the previous work of Capolongo et al [15] and were confirmed by other investigators (Fig. (3)) [16].…”

Section: 4-dhps As Multi Drug Resistance Reverterssupporting

confidence: 93%

1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story So Far And Perspectives (Part 2): Action in Other Targets and Antitargets

Carosati¹,

Ioan²,

Micucci³

et al. 2012

CMC

129

View full text Add to dashboard Cite

show abstract

“…MDR often develops in cancer cells to different chemotherapeutic drugs and is essential factor in the failure of various chemotherapies [25], including those based on DOXO. In the last two decades some 1,4-DHPs and structurally related compounds were discovered and approved as effective reversers of resistance to doxorubicin, daunomycin, vinblastine, and vincristine, as other anticancer drugs [25, 38, 39]. The presence of a hetaryl group at position 4of DHP is claimed as effectively increasing MDR-inhibiting activity [25].…”

Section: Discussionmentioning

confidence: 99%

Dihydropyridine Derivatives as Cell Growth Modulators In Vitro

Bruvere

Bisenieks

Poikāns

et al. 2017

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

The effects of eleven 1,4-dihydropyridine derivatives (DHPs) used alone or together with prooxidant anticancer drug doxorubicin were examined on two cancer (HOS, HeLa) and two nonmalignant cell lines (HMEC, L929). Their effects on the cell growth (3H-thymidine incorporation) were compared with their antiradical activities (DPPH assay), using well-known DHP antioxidant diludine as a reference. Thus, tested DHPs belong to three groups: (1) antioxidant diludine; (2) derivatives with pyridinium moieties at position 4 of the 1,4-DHP ring; (3) DHPs containing cationic methylene onium (pyridinium, trialkylammonium) moieties at positions 2 and 6 of the 1,4-DHP ring. Diludine and DHPs of group 3 exerted antiradical activities, unlike compounds of group 2. However, novel DHPs had cell type and concentration dependent effects on 3H-thymidine incorporation, while diludine did not. Hence, IB-32 (group 2) suppressed the growth of HOS and HeLa, enhancing growth of L929 cells, while K-2-11 (group 3) enhanced growth of every cell line tested, even in the presence of doxorubicin. Therefore, growth regulating and antiradical activity principles of novel DHPs should be further studied to find if DHPs of group 2 could selectively suppress cancer growth and if those of group 3 promote wound healing.

show abstract

Design, synthesis, spectral characterization and molecular docking studies of novel pyranoquinolinyl dihydropyridine carboxylates as potential antibacterial agents including Vibrio cholerae with minimal cytotoxity towards fibroblast cell line (L-929)

Lavanya¹,

Magesh²,

Venkatapathy³

et al. 2021

Bioorganic Chemistry

View full text Add to dashboard Cite

Reversal of Multidrug Resistance by New Dihydropyridines with Low Calcium Antagonist Activity

Cited by 4 publications

References 8 publications

1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story So Far And Perspectives (Part 2): Action in Other Targets and Antitargets

1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story So Far And Perspectives (Part 2): Action in Other Targets and Antitargets

Dihydropyridine Derivatives as Cell Growth Modulators In Vitro

Design, synthesis, spectral characterization and molecular docking studies of novel pyranoquinolinyl dihydropyridine carboxylates as potential antibacterial agents including Vibrio cholerae with minimal cytotoxity towards fibroblast cell line (L-929)

Contact Info

Product

Resources

About